Paclitaxel controlled-release - BTG

Drug Profile

Paclitaxel controlled-release - BTG

Alternative Names: DTS-301; Genexol/ReGel; OncoGel; Paclitaxel aqueous gel injection

Latest Information Update: 22 Jun 2011

Price : $50

At a glance

  • Originator BTG
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Oesophageal cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Glioblastoma; Oesophageal cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 07 Apr 2011 Discontinued - Phase-II for Oesophageal cancer in European Union (Intratumoural)
  • 07 Apr 2011 Discontinued - Phase-II for Oesophageal cancer in India (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top